SAN DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Metabasis Therapeutics
(NASDAQ:MBRX), a biopharmaceutical company focused on the
discovery, development and commercialization of novel drugs for the
treatment of metabolic and liver diseases by targeting the liver
and liver pathways, announced today that John Beck, senior vice
president of finance and chief financial officer of Metabasis will
present at the C.E. Unterberg, Towbin Emerging Growth Opportunities
Conference at the Mandarin Oriental Hotel in New York, NY. Mr. Beck
is scheduled to present on Wednesday, July 11, 2007 at 9:30 a.m.
Eastern Time, and is expected to provide an overview of the
Company's progress and discuss product candidates in clinical
development. Metabasis will also be participating in the Pacific
Growth Equities Cardiology & Metabolic Diseases Conference,
scheduled for Thursday, July 12, 2007 at the Grand Hyatt Hotel in
New York, NY.

To access the live audio broadcast and the subsequent archived
audio recording of the presentation, please log onto the Company's
website at www.mbasis.com under the "Investors" section. The audio
recording and presentation will be archived there for 30 days
following the live presentation. Please connect to Metabasis'
website several minutes prior to the start of the presentation to
ensure adequate time for any software download that may be
necessary.

About Metabasis (www.mbasis.com):

Metabasis Therapeutics is a biopharmaceutical company focused on
the discovery, development and commercialization of novel drugs to
address some of the world's most widespread and costly chronic
diseases involving pathways in the liver. The Company has
established a pipeline that includes clinical stage and preclinical
product candidates targeting major diseases with significant unmet
medical needs. Targeted diseases include major metabolic diseases
such as diabetes, hyperlipidemia and obesity as well as liver
diseases such as hepatitis and primary liver cancer. Metabasis has
developed several proprietary technologies for use in discovering
and optimizing drugs, including the NuMimetic(TM) and HepDirect(R)
technologies. Metabasis is continuing to identify and develop new
product candidates using its proprietary technologies and
expertise.